Evidence map›Paper›PMID 38201475›Full record

ArticleCancers2023

Cell-Free DNA Genomic Profiling and Its Clinical Implementation in Advanced Prostate Cancer.

Ivana Bratic Hench, Luca Roma, Floriana Conticelli, Lenard Bubendorf, Byron Calgua, Clémentine Le Magnen, Salvatore Piscuoglio, Mark A Rubin, Alin Chirindel, Guillaume P Nicolas and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Ivana Bratic HenchInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.ORCID 0000-0002-2062-027X
Luca RomaInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.ORCID 0000-0003-4632-5372
Floriana ConticelliInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Lenard BubendorfInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Byron CalguaInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Clémentine Le MagnenInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.ORCID 0000-0002-6084-6054
Salvatore PiscuoglioInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.ORCID 0000-0003-2686-2939
Mark A RubinPrecision Oncology Laboratory, Department for Biomedical Research, Bern Center for Precision Medicine, 3008 Bern, Switzerland.ORCID 0000-0002-8321-9950
Alin ChirindelDivision of Nuclear Medicine, Department of Theragnostics, University Hospital Basel, 4031 Basel, Switzerland.
Guillaume P NicolasDivision of Nuclear Medicine, Department of Theragnostics, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0003-0396-5708
Tatjana VlajnicInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.ORCID 0000-0002-1067-6771
Tobias ZellwegerSt. Claraspital, 4058 Basel, Switzerland.
Arnoud J TempletonSt. Claraspital, 4058 Basel, Switzerland.ORCID 0000-0002-0847-7087
Frank StennerDivision of Oncology, University Hospital Basel, 4031 Basel, Switzerland.
Christian RuizInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Cyrill RentschDepartment of Urology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.ORCID 0000-0002-8085-6006
Lukas BubendorfInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.ORCID 0000-0001-5970-1803
University of Basel · CHUniversity Hospital of Basel · CHUniversity of Bern · CHSt. Claraspital · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most men with prostate cancer (PCa), despite potentially curable localized disease at initial diagnosis, progress to metastatic disease. Despite numerous treatment options, choosing the optimal treatment for individual patients remains challenging. Biomarkers guiding treatment sequences in an advanced setting are lacking. To estimate the diagnostic potential of liquid biopsies in guiding personalized treatment of PCa, we evaluated the utility of a custom-targeted next-generation sequencing (NGS) panel based on the AmpliSeq HD Technology. Ultra-deep sequencing on plasma circulating free DNA (cfDNA) samples of 40 metastatic castration-resistant PCa (mCRPC) and 28 metastatic hormone-naive PCa (mCSPC) was performed. CfDNA somatic mutations were detected in 48/68 (71%) patients. Of those 68 patients, 42 had matched tumor and cfDNA samples. In 21/42 (50%) patients, mutations from the primary tumor tissue were detected in the plasma cfDNA. In 7/42 (17%) patients, mutations found in the primary tumor were not detected in the cfDNA. Mutations from primary tumors were detected in all tested mCRPC patients (17/17), but only in 4/11 with mCSPC. AR amplifications were detected in 12/39 (31%) mCRPC patients. These results indicate that our targeted NGS approach has high sensitivity and specificity for detecting clinically relevant mutations in PCa.

Indexed as

circulating cell-free DNAliquid biopsynext-generation sequencingprecision medicineprostate cancer

Identifiers

PMID38201475
PMCPMC10778564
OpenAlexW4390058724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.